Year: 2024
Type: article
Study design: Observational Study
Abstract: Background: SGLT-2 inhibitors are potent anti-hyperglycemic medicines that increase renal glucose excretion and enhance glycemic control. Concerns have been raised about an increased incidence of urinary tract infections in individuals who use these drugs. Objective: The aim of this study was to find out the frequency of UTI amongst patients taking SGLT 2 inhibitors. Material and method: The current cross sectional study was carried out at the department of medicine Ghulamm Muhammad Mahar medical college sukkur from January 2024 to June 2024 after taking permission from the ethical board of the institute. Participants of the study provided written informed permission. A total of 130 Individuals with type 2 diabetes of both genders and different age groups who were treated with sodium-glucose cotransporter-2 inhibitors alone or in combination with other drugs were included. Participants were instructed to collect midstream urine samples in a sterile the tube for microbiological analysis. A questionnaire was devised to collect patient history and demographic data. Data was entered and analyzed using SPSS version 25. Quantitative variables such as age were presented as mean ± SD. Qualitative factors such as gender, family history of diabetes, duration of diabetes, symptoms, and frequency of UTIs were provided as percentages. The Chi-square test was performed to evaluate the relationship between UTI, SGL T2 inhibitors, and other factors. P-values < 0.05 were considered significant. Results: A total of 130 individuals were enrolled in the current study out of which 60 (46.1%) were male and 70(53.8%) were females. out of the total individuals, 27 (20.7%) used Empagliflozin, whereas 103 (79.2%) took Dapagliflozin. In males 4(6.6%) had UTI while in females 10(14%) had urinary tract infection. Of 52(40%) diabetic individuals with a family history of diabetes, 10(19%)7, experienced a urinary tract infection. Among individuals with diabetes for 6-10 years, 3 (9%) experienced UTI. Among individuals with diabetes for more than ten years, four (23%) experienced UTI. Among 27(20.7%) diabetic patients on Empagliflozin, 4(14.8%) experienced urinary tract infection and those receiving Dapagliflozin,10(9.7%) experienced urinary tract infections Conclusion: The present study evaluated that 10% of diabetes individuals taking SGLT 2 inhibitors experienced urinary tract infections. More research is needed to determine the prevalence of UTIs in diabetes people.
Source: Cuestiones de Fisioterapia
DOI: 10.48047/7w7d9730
Language: English
Subfield: Epidemiology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
OpenAlex ID: W4412148228